Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387270 · ClinicalTrials.gov registry record · Phase 1
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
A Phase 1 study, sponsored by Medivation.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00387270 is a Phase 1 study that has completed, run by Medivation. The registered enrollment target is 9 participants.
The verdict
NCT00387270, a Phase 1 study, has completed, sponsored by Medivation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.
Interventions
- DRUG Dimebon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387270
The ClinicalTrials.gov registry entry for NCT00387270 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medivation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dimebon is the first listed.
NCT00387270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387270 about?
NCT00387270 is a clinical study titled "Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease". This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington'...
What is the current status of trial NCT00387270?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2006-10. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00387270?
The interventions under investigation include: Dimebon (DRUG).
Who is sponsoring clinical trial NCT00387270?
This trial is sponsored by Medivation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.